28855
document
Effect of daily etidronate on the osteolysis of multiple myeloma . Progressive bone disease in multiple myeloma frequently leads to osteolysis , bone resorption , pathologic fractures , vertebral compression , and hypercalcemia . We conducted a double-blind study in 173 newly diagnosed multiple myeloma patients of etidronate disodium ( EHDP ) , a diphosphonate compound that reduces bone resorption by inhibiting osteoclastic activity . The patients were randomly assigned to receive oral EHDP 5 mg/kg/d or placebo until death or discontinuation due to intolerance or refusal . The extent of vertebral deformity was measured by a vertebral index as well as height . The frequency of pathologic fractures , hypercalcemia , and bone pain was regularly assessed , as well as size and number of osteolytic lesions . All patients received melphalan and prednisone daily for 4 days every 4 weeks as the primary chemotherapy for their disease . Although the repeated measures analysis showed a significant height loss , there was no difference between treatment arms ( P = .98 ) . There was no significant difference in bone pain , episodes of hypercalcemia , or development of pathologic fractures . Patients on EHDP showed less deterioration in their vertebral index , but this difference only approached statistical significance ( P = .07 ) . We conclude that EHDP therapy used in this dosage schedule does not have a clinically significant impact in multiple myeloma .
28856
Intervention_Pharmacological
etidronate
28857
Intervention_Pharmacological
oral EHDP 5 mg/kg/d
28858
Intervention_Control
placebo
28859
Intervention_Pharmacological
melphalan
28860
Intervention_Pharmacological
prednisone
28861
Intervention_Pharmacological
EHDP
28862
Intervention_Pharmacological
EHDP
28863
Outcome_Physical
frequency of pathologic fractures
28864
Outcome_Physical
hypercalcemia
28865
Outcome_Physical
bone pain
28866
Outcome_Physical
height loss
28867
Outcome_Physical
bone pain
28868
Outcome_Physical
episodes of hypercalcemia
28869
Outcome_Physical
development of pathologic fractures
28870
Outcome_Physical
deterioration in their vertebral index
28871
Participant_Sample-size
173
28872
Participant_Condition
multiple myeloma
28873
Participant_Condition
etidronate disodium ( EHDP )
28874
Participant_Condition
Patients on EHDP